TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9280743

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (prepidil gel) plus oxitocin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous oxitocin
Number of subjects: 30
Study: 8397562

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg oral dose)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Terbutaline (subcutaneous injection)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 52
Study: 3628702

Group type: EXPERIMENTAL
Intervention: Policy 1 (erythromycin, nitrofurantoin substituted for trimethoprim and ampicillin)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Policy 2 (Augmentin - ampicillin + clavulinic acid substituted for trimethoprim and ampicillin)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pre-policy period
Number of subjects: 2
Study: 31094286

Group type: EXPERIMENTAL
Intervention: Cycloplegic auto‐refraction
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Non‐cycloplegic auto‐refraction (NCAR)
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (UCVA)
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Combination of UCVA and NCAR
Number of subjects: 2248
Study: 29203689

Group type: EXPERIMENTAL
Intervention: Novel interactive visualization of ESCAPE trial data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional visualization of ESCAPE trial data
Number of subjects: 0
Study: 27452202

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C ≥2.6/3.1 mmol/L)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 216
Study: 24666814

Group type: EXPERIMENTAL
Intervention: Tip variant
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Perihilar variant
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: NOS variant
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 111
Study: 22082200

Group type: EXPERIMENTAL
Intervention: Sustained-release oxycodone tablets (initial dose of 10mg orally every 12 hours, titrated according to pain intensity)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sustained-release oxycodone tablets
Number of subjects: 80
Study: 19329063

Group type: EXPERIMENTAL
Intervention: Boston Simplus (Bausch & Lomb) multipurpose solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Boston Advance (Boston) care system
Number of subjects: 18
Study: 17454160

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)/norethisterone acetate (NETA) (50 microg E2 daily for 14 days followed by 50 microg E2/0.25 microg NETA daily for 14 days; transdermal group, n = 19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Transdermal continuous E2/oral medroxyprogesterone acetate (MPA) (50 microg E2/5 mg MPA daily; transdermal/oral group, n = 19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Oral continuous E2/NETA (1 mg E2/0.5 mg NETA daily; oral group, n = 21)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Overall effects of HRT
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Increased-risk group (WC <88 cm, n = 32)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-risk group (WC >=88 cm, n = 27)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Subcutaneous fat <33 mm (n = 29)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Subcutaneous fat >=33 mm (n = 30)
Number of subjects: 59
Study: 14962821

Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rifapentine 900 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rifapentine 1200 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rifapentine (all doses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rifapentine
Number of subjects: 35
Study: 11856080

Group type: EXPERIMENTAL
Intervention: Balsalazide, 6.75 g
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sulfasalazine, 3 g
Number of subjects: 50
Study: 9788001

Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 286
Study: 8711365

Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine (PPC) 2.7 g daily for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2532946

Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST) positive
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST) negative
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 335247

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg given twice daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 30709403

Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention targeting increased whole plant food intake
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 28556488

Group type: EXPERIMENTAL
Intervention: Rabbit anti-human thymocyte immunoglobulin (rATG)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Basiliximab
Number of subjects: 1
Study: 25776840

Group type: EXPERIMENTAL
Intervention: Qingre Quyu Granule (QQG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 96
Study: 24325795

Group type: EXPERIMENTAL
Intervention: High intensity, 40 s, buccal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low intensity, 40 s, lingual
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental groups (not specified)
Number of subjects: 60
Study: 22336009

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with Alutard SQ, ALK-Abell¨®
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Chanllergen-Df drops, Wolwo Pharma
Number of subjects: 98
Study: 19500919

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 68
Study: 17999779

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC 1.8 g.day(‐1), 3 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (LIP 1.2 g.day(‐1), 3 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: taurine (TAU 3 g.day(‐1), 3 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (CON, placebo)
Number of subjects: 55
Study: 15697072

Group type: COMPARATOR
Intervention: Flutamide 250 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg three times daily
Number of subjects: 30
Study: 11696874

Group type: EXPERIMENTAL
Intervention: Inhaled iron oxide particles with high soluble iron content
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled iron oxide particles with low soluble iron content
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inhaled iron oxide particles (both high and low soluble iron)
Number of subjects: 16
Study: 9043725

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sevoflurane + N2O
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoflurane + N2O
Number of subjects: 24
Study: 8198915

Group type: EXPERIMENTAL
Intervention: Avoidance of packing the external auditory meatus and concha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Packing the external auditory meatus and concha
Number of subjects: 0
Study: 2903202

Group type: EXPERIMENTAL
Intervention: Celiprolol (5%)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Timolol (0.5%)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28650073

Group type: EXPERIMENTAL
Intervention: Relationship education program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 32
Study: 27569726

Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate Delayed Release (CBDR)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 24738317

Group type: COMPARATOR
Intervention: Nasal packing group (marcel materials used for nasal packing after septoplasty)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Septal suture group (septal suture technique performed after septoplasty)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: VSD group (one drainage tube used for negative pressure sucking after septoplasty without nasal packing)
Number of subjects: 90
Study: 23853057

Group type: EXPERIMENTAL
Intervention: 2000mg of American ginseng
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 20629971

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) with mycophenolate mofetil (MMF)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) with azathioprine (Aza)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: D+/R- combination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Preemptive strategy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Altered renal function
Number of subjects: 300
Study: 18923348

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic colorectal surgery
Number of subjects: 0
Study: 16164659

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 129

Group type: COMPARATOR
Intervention: Calcium containing phosphate binders
Number of subjects: 129
Study: 14513039

Group type: EXPERIMENTAL
Intervention: I‐FISH on peripheral blood neutrophils
Number of subjects: 0

Group type: COMPARATOR
Intervention: I‐FISH on unselected PB white cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytogenetics
Number of subjects: 0
Study: 10994909

Group type: EXPERIMENTAL
Intervention: Light exercise (50 biceps curls with a 5-lb dumbbell)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Immobilization (arm placed in a cast and supported in a sling at 90 degrees)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no restriction of arm activity)
Number of subjects: 26
Study: 8849766

Group type: EXPERIMENTAL
Intervention: Invited group (mammography screening)
Number of subjects: 15795

Group type: COMPARATOR
Intervention: Control group (no mammography screening)
Number of subjects: 15795

Group type: COMPARATOR
Intervention: General Swedish women
Number of subjects: 15795
Study: 1593749

Group type: EXPERIMENTAL
Intervention: Pimobendan (2.5 mg, intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril (12.5 mg, orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of pimobendan and captopril
Number of subjects: 0
Study: 6321686

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen (20 mg/m2 on days 2-6) and premarin (0.625 mg every 12 hours for three days on day 7)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Chemotherapy (cytoxan 750 mg/m2 and Adriamycin 30 mg/m2 on day 1 plus 5‐fluorouracil 500 mg/m2 and methotrexate 40 mg/m2 on day 8)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen and premarin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 110
Study: 31820334

Group type: EXPERIMENTAL
Intervention: Telemonitored exercise rehabilitation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine follow-up (Control)
Number of subjects: 96
Study: 31357402

Group type: COMPARATOR
Intervention: Usual-salt diet (1.2% salt)
Number of subjects: 97
Study: 26925988

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for family caregivers
Number of subjects: 82
Study: 26516308

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 30 mg/kg followed by 10 mg/kg/h continuous infusion until the end of surgery
Number of subjects: 146

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg
Number of subjects: 146
Study: 23855066

Group type: COMPARATOR
Intervention: Inflated Vest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Jacket
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 21291422

Group type: COMPARATOR
Intervention: Isoflurane preconditioning and propofol postconditioning (group IP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol treatment (group P)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Isoflurane treatment (group I)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 120
Study: 20187487

Group type: EXPERIMENTAL
Intervention: Cognitive self-assessment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cognitive-motor self-assessment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Retention (2 weeks later)
Number of subjects: 86
Study: 17121064

Group type: EXPERIMENTAL
Intervention: Sertaconazole nitrate cream 2% applied twice daily for 4 weeks
Number of subjects: 588

Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 4 weeks
Number of subjects: 588
Study: 12734156

Group type: EXPERIMENTAL
Intervention: Morphine PCA alone (Group I, n = 15)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Morphine PCA plus a continuous basal infusion (Group II, n = 14)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 35
Study: 10348755

Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (low target arm)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (middle target arm)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (high target arm)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Delavirdine monotherapy (pooled arms)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nucleoside control therapy (zidovudine or didanosine)
Number of subjects: 113
Study: 8664036

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 200 or 300 mg/m2/day by prolonged ambulatory infusion with radiotherapy (60-66 Gy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with radiotherapy
Number of subjects: 39
Study: 1960007

Group type: EXPERIMENTAL
Intervention: High-dose yohimbine (peak dose, 43 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 6264376

Group type: EXPERIMENTAL
Intervention: Glucose-containing oral rehydration solution
Number of subjects: 784

Group type: COMPARATOR
Intervention: Sucrose-containing oral rehydration solution
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Both glucose and sucrose solutions
Number of subjects: 784
Study: 6500778

Group type: EXPERIMENTAL
Intervention: Vincamine teprosilate (Teproside) at 120 mg daily for 90 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29616706

Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26291330

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing CHC
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 24862170

Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverages (NNS)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Water
Number of subjects: 303
Study: 22651831

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 19997751

Group type: EXPERIMENTAL
Intervention: Digital Image Cytometry (DICM)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Diploid DICM
Number of subjects: 93
Study: 18598318

Group type: EXPERIMENTAL
Intervention: Avecor oxygenator with Trillium (Medtronic)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Monolyth oxygenator (Sorin)
Number of subjects: 200
Study: 15791697

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12527244

Group type: EXPERIMENTAL
Intervention: DonJoy Legend functional brace
Number of subjects: 4
Study: 10574653

Group type: EXPERIMENTAL
Intervention: MCT (8:0 + 10:0)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 12:0
Number of subjects: 18
Study: 8531542

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1987947

Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 1% MK-927
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.5% MK-927
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 7051722

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30835880

Group type: EXPERIMENTAL
Intervention: Fresh RBCs
Number of subjects: 90

Group type: COMPARATOR
Intervention: Aged RBCs
Number of subjects: 90
Study: 30157910

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) alongside chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alongside chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-randomised open-label arm (ZA or placebo for those who decline chemotherapy)
Number of subjects: 0
Study: 27020840

Group type: EXPERIMENTAL
Intervention: PhysioDirect telephone assessment and advice service
Number of subjects: 2252

Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 2252
Study: 25216281

Group type: EXPERIMENTAL
Intervention: Computerised Clinical Decision Support (CCDS) for paramedics
Number of subjects: 779

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: CCDS
Number of subjects: 779
Study: 23035666

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 20423524

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention consisting of print resources and four weekly 30-minute telephone support calls.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group receiving printed nutrition information only.
Number of subjects: 400
Study: 17297002

Group type: EXPERIMENTAL
Intervention: Inversion-recovery MR imaging
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Substantia nigra/midbrain area ratio
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lateral/medial pixel-intensity ratio
Number of subjects: 8
Study: 16140526

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg subcutaneously)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Chemoradiation without amifostine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Chemoradiation with amifostine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Amifostine administration
Number of subjects: 54
Study: 14642140

Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T(50))
Number of subjects: 28
Study: 10430112

Group type: EXPERIMENTAL
Intervention: 200 mg celecoxib twice a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 400 mg celecoxib twice a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen twice a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7555513

Group type: EXPERIMENTAL
Intervention: 50/50 human insulin mixture (0.3 U/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 70/30 human insulin mixture (0.3 U/kg)
Number of subjects: 20
Study: 2188525

Group type: EXPERIMENTAL
Intervention: Epidural morphine with 2.5 mg droperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural morphine with placebo
Number of subjects: 40
Study: 6457384

Group type: EXPERIMENTAL
Intervention: Needle acupuncture at correct sites according to Chinese medicine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo needles at the same sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture needles applied at inconsistent sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laser rays at correct acupuncture sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Red light at correct acupuncture sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mixed light at correct acupuncture sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Infrared at correct acupuncture sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No radiation at all
Number of subjects: 120
Study: 31098977

Group type: EXPERIMENTAL
Intervention: PACT-Intensive Management (PIM)
Number of subjects: 2566

Group type: COMPARATOR
Intervention: PACT
Number of subjects: 2566
Study: 28438476

Group type: EXPERIMENTAL
Intervention: Education of families by tab
Number of subjects: 74

Group type: COMPARATOR
Intervention: Education of families by routine
Number of subjects: 74
Study: 25160713

Group type: EXPERIMENTAL
Intervention: Aberration-correcting IOLs
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Aberration-free IOLs
Number of subjects: 198

Group type: COMPARATOR
Intervention: Spherical IOLs
Number of subjects: 198
Study: 23874850

Group type: EXPERIMENTAL
Intervention: Uphill running at 70% VO2max on 0% slope
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Uphill running at 70% VO2max on 2% slope
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Uphill running at 70% VO2max on 7% slope
Number of subjects: 18
Study: 21443330

Group type: EXPERIMENTAL
Intervention: Ongoing task delay (lengthened)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filler task delay (lengthened)
Number of subjects: 0
Study: 17851459

Group type: EXPERIMENTAL
Intervention: Simulated low-glycaemic index (GI) breakfast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simulated high-glycaemic index (GI) breakfast
Number of subjects: 40
Study: 16306933

Group type: EXPERIMENTAL
Intervention: Long-term mild hypothermia (n = 108) for 5±1.3 days
Number of subjects: 215

Group type: COMPARATOR
Intervention: Short-term mild hypothermia (n = 107) for 2±0.6 days
Number of subjects: 215

Group type: COMPARATOR
Intervention: Short-term mild hypothermia (n = 107)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Long-term mild hypothermia (n = 108)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Long-term mild hypothermia vs Short-term mild hypothermia
Number of subjects: 215